公司诉讼背景 - 律师事务所Robbins Geller宣布针对KinderCare Learning Companies Inc的集体诉讼 原告需在2025年10月14日前申请担任首席原告[1] - 诉讼指控公司及高管、董事、控股股东和IPO承销商违反1933年证券法[1] IPO详情 - 公司通过IPO向投资者出售超过2700万股普通股 每股价格24美元 募集资金总额达6.48亿美元[2] 诉讼核心指控 - 指控公司IPO注册声明存在虚假和/或误导性陈述 未能披露多项儿童虐待、忽视和伤害事件[3] - 公司未能提供其宣称的"最高质量护理" 甚至未能达到 childcare 行业最低标准或遵守相关法律法规[3] - 未披露公司面临重大诉讼风险、监管行动、负面舆论、声誉损害和业务损失[3] 股价表现 - IPO后公司股价下跌至接近每股9美元的低点[4] 原告代表信息 - 原告由Robbins Geller律师事务所代理 该所在投资者集体诉讼和金融欺诈案件方面拥有丰富经验[4]

If you purchased or otherwise acquired Novo Nordisk securities during the Class Period, you may move the Court no later than September 30, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. LOS ANGELES, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S ("Novo Nordisk" o ...

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lockheed Martin Corporation ("Lockheed Martin Corporation" or the "Company") (NYSE: LMT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lockheed Martin Corporation investors who were adversely affected by alleged securities fraud between January 23, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team: CONTACT: ...

WHAT'S NEXT? If you suffered a loss in Biohaven Ltd. during the relevant time frame, you have until September 12, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifi ...

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neogen Corporation ("Neogen Corporation" or the "Company") (NASDAQ: NEOG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neogen Corporation investors who were adversely affected by alleged securities fraud between January 5, 2023 and June 3, 2025. Follow the link below to get more information and be contacted by a member of our team: WHAT'S NEXT? If you suffered a los ...

NEW YORK , Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Tesla, Inc. ("Tesla, Inc." or the "Company") (NASDAQ: TSLA) of a class action securities lawsuit. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Tesla overstated the effectiveness of its autonomous driving technology; (ii) there was thus a significant risk that the Company's autonomous driving vehicles, including the Robotaxi, would operate dangerously and/or in vi ...

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP ("XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP" or the "Company") (NYSE: XIFR) of a class action securities lawsuit. WHAT'S NEXT? If you suffered a loss in XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP during the relevant time frame, you have until September 8, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share ...

诉讼案件概述 - 针对Replimune Group Inc (NASDAQ: REPL)的证券集体诉讼案件已启动 涉及2024年11月22日至2025年7月21日期间因涉嫌证券欺诈遭受损失的投资者 [1] - 诉讼指控公司管理层在IGNYTE临床试验前景方面存在虚假陈述和/或隐瞒行为 [2] 指控内容 - 公司被指控 recklessly 夸大IGNYTE试验的成功可能性 尽管已知或应知该试验存在重大缺陷 [2] - 美国FDA认定IGNYTE试验设计不充分且缺乏良好控制 导致公司关于业务运营和前景的陈述存在 materially false and misleading [2] 诉讼程序 - 受影响投资者需在2025年9月22日前申请成为首席原告 但参与赔偿无需担任首席原告角色 [3] - 集体诉讼成员可能获得赔偿且无需承担自付费用 [3] 律所背景 - Levi & Korsinsky律所过去20年累计为受损股东追回数亿美元赔偿 在证券集体诉讼领域保持全美前50强排名 [4] - 该律所拥有70多名专业人员 连续7年被ISS Securities Class Action Services评为顶级证券诉讼律所 [4] 联系方式 - 案件联系信息包括纽约办公室地址 电话(212)363-7500 及电子邮箱 [5]

集体诉讼案件 - 针对Centene Corporation的集体诉讼案件涉及2024年12月12日至2025年6月30日期间因涉嫌证券欺诈而遭受损失的投资者 [1] - 诉讼指控被告向投资者提供了过于乐观的陈述 同时传播了重大虚假和误导性陈述 和/或隐瞒了有关公司真实参保率和发病率的重要不利事实 [2] 公司财务影响 - 2025年7月1日 Centene发布新闻稿撤回2025年业绩指引 导致股价大幅下跌 [2] - 根据对2025年健康保险市场的分析 公司在22个州(占其市场会员的72%)的整体市场增长低于预期 [2] - 初步分析导致公司将其先前发布的指引下调至约18亿美元 或调整后稀释每股收益2.75美元 [2] - 公司股价从2025年7月1日的56.65美元/股暴跌至2025年7月2日的33.78美元/股 跌幅达40.4% [2] 律师事务所信息 - Levi & Korsinsky律师事务所在过去20年中为受损股东追回了数亿美元 并建立了赢得高风险案件的记录 [4] - 该律所拥有代表投资者处理复杂证券诉讼的丰富专业知识 拥有70多名员工组成的团队 [4] - 连续七年被ISS证券集体诉讼服务评为美国顶级证券诉讼律所之一 [4]

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between May 7, 2025 and July 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?pri ...